ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of testicular seminoma

Annals of Oncology

Volumn 16, Issue SUPPL. 1, 2005, Pages

  Huddart, R A ^a,c   Kataja, V V ^b,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c ESMO Guidelines Task Force   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN;

ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RISK ASSESSMENT; SEMINOMA; TESTIS BIOPSY; TREATMENT PLANNING; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; RISK ASSESSMENT; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 21044453189     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi832     Document Type: Article

References (10)

1. Group IGCC. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
2. Fossa SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999; 17: 1146-1154.
3. Warde P, Gospodarowicz M, Panzarella T. Management of stage II seminoma. J Clin Oncol 1998; 16: 716-724.
4. Horwich A, Oliver RT, Fossa SD et al. A Medical Research Council randomized of single agent carboplatin versus etoposide (E) and cisplatin for advanced metastatic seminoma. BJC 2000; 83: 1623-1629.
5. O'Sullivan JM, Huddart RA, Norman AR et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumors. Ann Oncol 2003; 14: 91-96.
6. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
7. Jones WG, Fossa SD, Mead GM et al. A randomized trial of 30Gy vs 20Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18 EORTC 30 942). J Clin Oncol 2005; 23: 1200-1208.
8. Oliver RT, Mason M, Von Der Maase et al. A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treament of stage I seminoma of testis following orchidectomy TE19/EORTC 30 982. Proc Am Soc Clin Oncol 2003; 22(14S): p386s.
9. Warde P, Specht L, Horwich A et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis. J Clin Oncol 2002; 20: 4448-4452.
10. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial. J Clin Oncol 2004; 22: 1034-1039.